(Q39396013)

11 September 2017

title

Safety, efficacy and costs of pharmacotherapy for functional gastrointestinal disorders: the case of alosetron and its implications (English)

1 reference

11 September 2017

0 references

1 reference

U. Ladabaum

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12694084

23 December 2023

language of work or name

English

0 references

publication date

1 April 2003

1 reference

full work available at URL

11 September 2017

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1046/j.1365-2036.2003.01545.x

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12694084

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2036.2003.01545.x

23 December 2023

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01545.X

https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2036.2003.01545.x

23 December 2023

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01545.X

Alimentary Pharmacology & Therapeutics

23 December 2023

published in

1 reference

11 September 2017

volume

17

1 reference

11 September 2017

issue

8

1 reference

11 September 2017

page(s)

1021-1030

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01545.X

11 September 2017

1 reference

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01545.X

Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01545.X

Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01545.X

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01545.X

A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01545.X

Lotronex and the FDA: a fatal erosion of integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01545.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01545.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01545.X

Costs of care for irritable bowel syndrome patients in a health maintenance organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01545.X

Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01545.X

Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01545.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01545.X

Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01545.X

American Gastroenterological Association medical position statement: irritable bowel syndrome

21 January 2018

1

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01545.X

The burden of selected digestive diseases in the United States.

23 December 2023

4

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01545.X

Management of the irritable bowel syndrome

23 December 2023

6

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01545.X

23 December 2023

13

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01545.X

23 December 2023

14

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01545.X

23 December 2023

16

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01545.X

23 December 2023

17

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01545.X

Recommendations of the Panel on Cost-effectiveness in Health and Medicine

23 December 2023

20

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01545.X

Primer on Medical Decision Analysis: Part 3—Estimating Probabilities and Utilities

23 December 2023

21

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01545.X

Primer on medical decision analysis: Part 4--Analyzing the model and interpreting the results

23 December 2023

22

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01545.X

A general health policy model: update and applications

23 December 2023

25

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01545.X

The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors.

23 December 2023

26

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01545.X

Impact of irritable bowel syndrome on quality of life

23 December 2023

27

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01545.X

Predicting Quality of Well-being scores from the SF-36: results from the Beaver Dam Health Outcomes Study

23 December 2023

28

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01545.X

The impact of irritable bowel syndrome on health-related quality of life

23 December 2023

29

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01545.X

How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations

23 December 2023

37

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01545.X

Five‐Hundred Life‐Saving Interventions and Their Cost‐Effectiveness

23 December 2023

39

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01545.X

Can the standard gamble be used to determine utilities for uncertain health states? An example using postoperative maintenance therapy in Crohn's disease

23 December 2023

40

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01545.X

Utilities and quality-adjusted life years

23 December 2023

42

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01545.X

EuroQol--a new facility for the measurement of health-related quality of life

23 December 2023

43

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01545.X

Physicians' diagnostic judgments and treatment decisions for acute otitis media in children

23 December 2023

45

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01545.X

23 December 2023

Identifiers

1 reference

11 September 2017

1 reference